Abstract 3489
Background
ADT prior to mets may not improve QoL or OS in BCR prostate cancer and may result in irreversible adverse events at high costs. Early use of novel androgen receptor targeting drugs (NARTD) prolonged MFS in nonmetastatic-castration resistant prostate cancer (nmCRPC). However, clinical details prior to castration resistance and explicit criteria for starting ADT were not given. We hypothesize that deferring ADT until mets results in outcomes comparable to those reported with early ADT, irrespective of NARTD used in nmCRPC.
Methods
Retrospective review of men who underwent RP from1983 - 2014 within Johns Hopkins and the Center for Prostate Disease Research Multi-Center National Database, developed BCR and did not receive ADT until metastasis. Kaplan-Meier estimates of MFS and OS were defined from RP to event/last follow-up. Multivariable Cox proportional hazard models identified predictive factors.
Results
2,930 men fulfilled eligibility criteria: median age 61,17% African American, Gleason 6 (29%),7 (52%), 8-10 (18%), + margins 38%, median PSADT 27 mos. With a median F/U of 10 years, 20% developed M+ and received ADT, 27% died. Median MFS was 24 yrs (21-27 yrs) and median OS was 21 yrs (20-22 yrs) (Table). Age at surgery, pT stage, Gleason sum, surgical margin status and PSADT significantly predicted OS (p<.03). pT stage, Gleason sum, time to BCR, race and PSADT predicted MFS (p < 0.01).Table:
852P
PSADT | |||
---|---|---|---|
Overall | < =6 months | < =10 months | |
# developed M + | 595 (20%) | 198 (45%) | 309 (38%) |
Median MFS (all) | not reached | 12 (8-16) years | 16 (15-21) years |
Median MFS (M+ only) | 6 (6-7) years | 3 (3-4) years | 4 (4-5) years |
Median OS | 21 (20-22) years | 14 (12-17) years | 17 (15-18) years |
Conclusions
Deferred ADT until time of metastases results in long MFS and OS even with short PSADT suggesting that it remains possible that prolongation of MFS in nmCRPC may not reflect true overall net therapeutic benefits which requires prospective study to define specific patient selection and criteria for initial ADT implementation, control of post progression management and QoL/OS information.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C.H. Marshall: Research grant / Funding (self): Conquer Cancer Foundation (Bristol Meyers Squibb); Travel / Accommodation / Expenses: Dava Oncology; Advisory / Consultancy: McGraw Hill. B. Trock: Advisory / Consultancy, Research grant / Funding (institution): Myriad Genetics; Research grant / Funding (institution): MDx Health. All other authors have declared no conflicts of interest.
Resources from the same session
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract